et al.. UMD-DYSF, a novel locus specific database for the compilation and interactive analysis of mutations in the dysferlin gene.
INTRODUCTION
In 1998, the groups of Robert H. Brown Jr. (Liu, et al., 1998) and Kate Bushby (Bashir, et al., 1998) identified the g enetic ca use o f th e a utosomal recess ive muscle-wasting di seases M iyoshi myopathy (MIM# 254130 ), an d Limb Girdle Muscular Dystrophy type 2B (LGMD2B; MIM# 253601) as resulting from mutations in a novel gene on ch romosome 2p13. T he en coded prot ein was named dy sferlin ( DYSF; MIM# 6030 09), rel ating t o i ts involvement i n muscular d ystrophy, an d h omology with t he C. el egans f er-1 prot ein. Using membrane repai r assays o n muscle f ibers from d ysferlin-deficient mouse models, th e g roups o f P aul McNeil/Ke vin Campbell (Bansal, et al., 20 03) and Robert H. B rown Jr. (Lennon, et al., 2003) subsequently demonstrated a central role for dysferlin in sarcolemmal repair after membrane injury. This established Miyoshi myopathy and LGMD2B as th e first entities of a new subgroup of muscular dystrophies, due to defective membrane-repair.
From a cl inical point of view, numerous reports corroborated the implication of mutated dysferlin in muscular dystrophy, and in particular in a high proportion of LGMD. In the past ten years, regular mutational analysis has allowed f or better ch aracterization of th e ph enotypic manifestations asso ciated with d eleterious mutations in t he DYSF gene. The main clinical presentations are the distal-onset muscular dystrophy called ,Miyoshi myopathy and the proximal-onset form LGMD2B, both characterized by progressive muscle weakness, usually appearing in the second decade, an d highly elevated serum creatine kinase (CK) levels. Progressively, the description of diff erent phenotypes caused by DYSF mutations Klinge, et al., 2008; Nguyen, et al., 2005; Nguyen, et al., 2007; Okahashi, et al., 2008; Paradas, et al., 2009; Seror, et al., 2008; Spuler, et al., 2008; Ueyama, et al., 2002; Wenzel, et al., 2007) , in addition to th e "typical" LGMD and Miyoshi phenotypes, unraveled a wide spectrum of phenotypes, ranging from clinically asymptomatic, isolated hyperCKemia to severe and early onset presentations (Bushby, 2000; L aval a nd Bu shby, 2004; U rtizberea, et al ., 200 8) . This wide ran ge of clinical pres entations i s collectively referred to as dysferlinopathies.
DYSF was initially shown to be expressed in the skeletal and cardiac muscle tissues (Bashir, et al., 1998; Liu, et al., 1998) , in monocytes (Ho, et al., 2002) , as well as in a variety of tissues, including liver, lung, kidney, pancreas, brain, and placenta (Bashir, et al., 19 98; Liu, et al., 1998) . More recent studies have isolated 14 is oforms that are differentially ex pressed a mong ti ssues. T hese is oforms orig inate f rom t he diff erential u se of prom oters an d alternative exons which have been identified, respectively DYSF (AF075575) (Foxton, et al., 2004) and DYSF_v1 (Pramono, et al ., 200 6) promoters, an d al ternative e xons 5 a an d 40a ( Pramono, et al ., 2 009) . Is oform 8, which contains the 55 ca nonical exons transcribed via the DYSF promoter, constitutes the major DYSF transcript (73%) among al l report ed i soforms expressed i n sk eletal muscle, bu t i s n ot ex pressed i n monocytes where i soform 13 (NM_001130980; containing exon 5a) represents the main dysferlin messenger (44%) (Pramono, et al., 2009) . The other isoforms are le ss expressed in s keletal muscle and blood. In addition to t he canonical messenger composed of 55 exons, splice variants lacking exon 17 are expressed at early stages of myogenic cell differentiation and also constitute p redominant d ysferlin tran scripts in mature p eripheral n erve tis sue (Salan i, et al., 20 04) . To date, th e functional role of the different messengers remains unknown.
Due to th e larg e s ize of t he DYSF g ene, which s pans a gen omic l ocus of approx imately 233k bp, m utation screening is c hallenging o n a ro utine cli nical b asis. M utational an alysis o f DYSF is further co mplicated b y t he large mutational s pectrum (det ailed i n t his art icle), an d a h igh proport ion of " private" mutations, which l eaves molecular geneticists with t he recu rrent d ifficulty o f i nterpreting novel DYSF s equence v ariants, i n particular putative splicing and missense variants.
Until now, the Leiden Open (source) Variation Database established in 1998 f or dysferlin (LOVD Dysferlin), has been t he un ique Locus Specif ic Databas e s erving as a pu blic repos itory f or hum an d ysferlin v ariants (www.lovd.nl/DYSF). O ur l aboratory, as many ot hers, widely us es t his valuable res ource. O n N ovember, 18, 2011, L OVD D ysferlin cons isted of 424 u nique sequence v ariants, including pu blished or directly s ubmitted (unpublished) v ariants, b eing eith er d isease-causing mutations ( ca. 300 v ariants) or p olymorphisms ( ca. 10 0 variants). W hile LOVD i s a n eff icient a nd co nvenient to ol f or g ene-centered co llection, cu ration an d d isplay o f DNA v ariation, d ata an alysis o ptions are li mited. T he Un iversal M utation Datab ase ( UMD®) L ocus Specific Databases (Beroud, et al., 2000; have been developed specifically to allow for the collection of mutational d ata an d p rovide n umerous b ioinformatics tools f or th e in teractive an alysis o f mutational d ata, including t he a nalysis o f novel sequence variants. E ven more, t he UM D® software is v ery f lexible f or the development of novel tools, based on questions arising in the research field.
In the present article, we describe the online version of UMD-DYSF, freely accessible at www.umd.be/DYSF/. In co mplement to LOVD D ysferlin, UMD -DYSF n ot o nly ref erences all p reviously p ublished d isease-causing mutations identified in the DYSF gene but also includes interactive bioinformatics tools for the analysis of DYSF sequence variants. I n particular, UMD-DYSF o ffers a c omputational procedu re f or th e an alysis o f pos sible deleterious mutations a ffecting sp licing signals in t he dysferlin g ene, u sing t he Hu man Sp licing Fi nder (HSF) algorithm (D esmet, et al ., 2009 ) an d i ntegrates t he U MD-Predictor t ool f or t he an alysis of missense variants (Frederic, et al., 2009 ). Furthermore, interactive functions allow for analysis of the full UMD-DYSF dataset, single mutational e vents o r c ustomized subsets o f mutations re ferenced in t he d atabase. W e p reviously used a n o ffline version of UMD -DYSF to successfully analyse the mutational spectrum of a large cohort of patients analysed for DYSF mutations in our diagnostic laboratory (Krahn, et al., 2009a ). To f urther illustrate the use of UMD-DYSF, we here report th e results of statistical analyses of the DYSF mutational sp ectrum b ased for the first ti me o n al l compiled DYSF disease-causing mutations reported in the literature to date.
THE UMD-DYSF DATABASE

Database description
The UMD-DYSF databas e was dev eloped u sing a s oftware pack age of specific rou tines, which allo ws optimized multicriteria s earch a nd s orting of dat a (Berou d, et al ., 2000; Berou d, et al ., 2005) . Mu tational dat a entries are standardized to f acilitate mutational an alysis, a s prev iously described (C ollod -Beroud, et al., 2003; Frederic, et al., 2008) . Each entry corresponds to one mutation associated with one affected individual, either index patient or a ffected relative. At the moment, UM D-DYSF includes DYSF mutations described or pre dicted in the literature as d eleterious, exclusively. However, in future versions, UMD-DYSF will include unpublished data for disease-causing variants (see the DATABASE UPDATE section). UMD-DYSF is currently not aimed at collecting polymorphism dat a from pat ients beca use c urrent di agnostic s creening methods are not h omogenized bet ween laboratories, an d res ults of polymorphism pat ient dat a are t herefore bi ased. F or users i nterested i n kn own polymorphism data, the UMD-DYSF website links to the UCSC genome browser page for DYSF (Dreszer, et a l., 2011) (http://genome.ucsc.edu) an d each UMD-DYSF mutation d escription p age li nks to th e co llection o f sequence variations available in LOVD Dysferlin for the corresponding nucleotide position. As d ysferlinopathies are an au tosomal reces sive dis ease, u sers s hould be w arned th at " polymorphism data" is sued f rom lar ge-scale "normal" co ntrol st udies can b e "contaminated" with tr uly p athogenic DYSF s equence v ariants f ound at a heterozygous state in healthy carriers. These variants should thus be confronted to pathogenicity prediction tools -such as those available in UMD-DYSF-to further evaluate the possibility of a deleterious effect.
The f ollowing mutational e vents ca n b e en tered i nto th e d atabase: p oint mutations, i nsertions, d eletions, an d insertions-deletions (i ntronic an d/or ex onic); a s well a s mono-o r multi-exonic l arge-sized d eletions o r duplications. Several levels of information are provided for each mutation, including the affected exon and codon number, wild-type an d mutant codon s equence, t ype o f mutational ev ent, mutation nomenclature, wild-type an d mutant a mino-acid, a ffected do main, etc. W henever ava ilable, we als o included i n t he databas e c linical information; however, in most publications, only the main phenotype data (i.e. LGMD2B or Mi yoshi myopathy), but no detailed information, are described. Mutational events are automatically described using the official nomenclature of the Human Genome Variation Society (den D unnen a nd A ntonarakis, 2000), an d relating t o t he human DYSF cDN A s equence of re ference (isoform 8, G enBank #N M_003494.2) w hich corres ponds t o t he major DYSF tran script am ong all rep orted isoforms expressed in skeletal muscle (Pramono, et al., 2009) . DYSF isoform 8 (6243b p) is transcribed under the DYSF promoter and contains the 55 canonical exons, with exons 5a and 40a exclusion and exon 17 inclusion. The dysferlin protein sequence was annotated for C2 domains, ferlin family domains, DysF domains and TM domain based on predi ctions f rom Pf am 25.0 (F inn, et al ., 201 0) and S MART 6 (L etunic, et al ., 200 9) an d f or h ighly conserved res idues ex pected to be involved i n ca lcium coordination as d escribed b y Therrien an d co lleagues (Therrien, et al., 200 6) . Us ers of UMD -DYSF ca n verify whether ex onic mutations a ffect ann otated s tructural domains or highly conserved residues.
Interactive a nalysis of DYSF mutational dat a i ncluded i n the dat abase was don e us ing prev iously des cribed sorting-and research-functions (Beroud, et al., 2000; Beroud, et al., 2 005) . In addition, the present version of the UMD-package includes novel routines to a ssist the design of new therapeutic tools. Analysis tools and functions accessible on the UMD-DYSF website are des cribed in T able 1, and a brief user guide can be do wnloaded from the website.
Table 1. Complete list of tools and functions available on the UMD-DYSF website (www.umd.be/DYSF/)
Function or tool name Function or tool description I found a mutation
Displays a table of the various mutational events registered in UMD-DYSF for a given position. I want to analyze the impact of a missense variant Uses the UMD-Predictor® algorithm to predict the pathogenicity of all possible non-synonymous or synonymous mutations from the DYSF gene. I want to analyze an intronic variant Uses the Human Splicing Finder tool to evaluate the consequences of substitutions on splicing. I want to search the database Allows the selection of a specific subset of the database. Results are displayed as a list on the screen. Predicted impact of all previously reported missense variations Uses the UMD-Predictor® tool to predict the pathogenicity of all UMD-DYSF missense variants localized in the coding sequence.
Global analysis
Gives a summary of mutation types. Position
Studies the distribution of mutations at the nucleotide level to identify preferential mutation sites.
Potential stop codons
Displays all codons from a specific exon that can be mutated into a stop codon by a single substitution.
Mutation map
Displays the distribution of the various mutations along the gene and the protein.
Deletion map
Displays the distribution of the various deletions along the gene and the protein.
Stop codon map
Displays the exon phasing and the position and number of reported nonsense mutations.
Geographic distribution
Displays geographic origin of patients.
Binary comparison
Displays the distribution of the various mutations along the gene for two chosen subsets of the database.
Stat exons
Studies the distribution of mutations in the different exons. It enables detection of a statistically significant difference between observed and expected mutations Distribution by exon Displays the partition of each type of mutation in each exon Structure
Studies the distribution of allelic mutations both in the various structural domains of the protein and in the highly conserved residues expected to be implicated in calcium coordination
Database entries
The UMD-DYSF v1.0 (April 12, 2011 ) contains a total of 742 en tries corresponding to mutational data from 558 patients diagnosed with primary d ysferlinopathy a nd previously reported in t he lite rature as disease-causing mutations. T he t otal n umber of pat ients a mounts t o 401 i ndex cas es (557 mutational e ntries) an d 157 rel atives. Among all UMD-DYSF entries, 192 entries from 129 patients correspond to mutations identified in our laboratory (Khadilkar, et al ., 2008; K rahn, et al ., 2009a; K rahn, et al., 2009b; K rahn, et a l., 2010; N guyen, e t al ., 2005; Nguyen, et al., 2007; Seror, et al., 2008) w hile the others correspond to m utational data reported in 55 addition al publications ( see www.umd.be/DYSF/ for a co mprehensive li st o f re ferences). All mutational d ata can b e visualized through the "Search" function described in Table 1 and downloaded from the UMD-DYSF website.
Bioinformatics tools for the interpretation of sequence variants
A recurrent p roblem in genetic d iagnosis i s the i nterpretation o f seq uence variants, including the d ifficulty i n predicting the impact of a genomic variation on the pre-mRNA maturation and the mRNA translation mechanisms, and in predicting any deleterious effect on the mRNA and protein stability. The Human Gene Mutation Database (professional rel ease 2010.4) which col lects al l known gene l esions res ponsible f or hum an i nherited di seases (Stenson, et al., 2009) , reports a total of 108046 mutational entries, 54% of which are missense mutations, as well as mutations affecting RNA splicing. Interpretation of the effect of DYSF missense variants and identification of DYSF splice variants is facilitated by a num ber of bioinformatics tools integrated into UMD-DYSF and available online.
The H SF t ool i s bas ed on U MD al gorithms a nd predi cts consequences of mutations aff ecting e xisting s plice signals (don or an d acceptor sites, bran chpoints a nd cis-acting ele ments s uch a s ex onic s plicing enh ancers an d silencers) or possibly creating novel ectopic splicing sequences. These algorithms are integrated into UMD-DYSF to allo w f or t he a nalysis o f sequence v ariants. Detailed a nalysis o f UMD -DYSF ab normal splicing variants i s described below.
To f urther dis criminate bet ween n eutral an d path ogenic sequence v ariations, UM D-DYSF als o integ rates th e recently developed UMD-Predictor tool (Frederic, et al., 2009 ). UMD-Predictor combines data such as localization within the protein, conservation and biochemical properties of the mutant and wild-type residues, as well as results from HSF analysis to calc ulate a path ogenicity score ranging from 0 to 100 f or each missense variant (score >65 indicates a p robable o r h ighly likely p athogenicity). Its e fficiency for p redicting p athogenic missense mutations was demonstrated by a se nsitivity of 95.4% and a p ositive predictive value of 99.5% (Frederic, et al., 2 009) . The UMD-Predictor s core was co mputed for all UMD -DYSF missense variant e ntries a nd can be con sulted on t he UMD-DYSF website using t he "Predicted Im pact o f al l Previously Rep orted Mis sense Variatio ns" fu nction. Although all variants predicted or described in the literature to be deleterious were entered into UMD-DYSF, 5% were predi cted as probabl e or l ikely pol ymorphisms us ing UMD-Predictor ( pathogenicity s core <65). These variants could correspond to true polymorphisms in patients for whom the accurate deleterious mutation has been missed du ring g enetic t esting (i ncomplete mutation det ection rates of pre-screening tec hniques s uch as Sing le Strand Conformation Polymorphism analysis or Denaturing High Pressure Liquid Chromatography; mutations not detected u sing rou tine s equencing approach es such as large g enomic rearran gements an d "deep" i ntronic mutations; etc.). Mo re likely, these variants spot cases for which the UMD-Predictor algorithm lacked predictive elements to accu rately i nterpret th e path ogenic e ffect of th e s equence v ariant. More gen erally, f or v ariants of unclear p athogenicity, d efinitive co nclusion o n their p ossible d eleterious eff ect will o nly b e ach ievable with integration o f novel fu nctional d ata in to th e UMD-Predictor alg orithm. I n p articular, b ioinformatics p redictions can greatly benefit from sequencing data of mutated DYSF RNAs and proteins, and from novel functional elements that would shed light on molecular roles and functions of dysferlin, do main organisation and critical residues o f the protein.
Bioinformatics routines to assist the design of therapeutic strategies
Two i nteresting t ools av ailable on t he U MD-DYSF website ( Table 1) h ave been des igned t o h elp dev elop certain t ypes o f t herapeutic a pproaches f or d ysferlinopathies. In partic ular, s everal nonsense mutations co uld be targets for pos sible t herapeutic approach es bas ed on a minoglycoside read t hrough o f s top codon s (Wan g, et al ., 2010) . The "Potential Stop Codon" function gives the list of codons that can lead to a premature termination codon (PTC) when mutated by a single substitution; along with the number of such mutations reported in UMD-DYSF. This function also p rovides st atistical calc ulation ab out the environment of observed PTC co mpared to potential PTC for which no mutation has ever been reported. The distribution of nonsense mutations reported in the DYSF gene is des cribed belo w. I n addition, th e "Stop C odon M ap" f unction is a UMD newly i mplemented tool t hat displays t he e xon p hasing a nd t he pos ition and number o f report ed nonsense mutations. T his function has been designed to facilitate envisaging exon skipping strategies (Aartsma-Rus, et al., 2010; Levy, et al., 2010; W ein, et al., 2010) .
Analysis of the DYSF mutational spectrum
General statistics
Mutational d ata f rom larg e c ohorts o f p atients rep eatedly revealed a larg e mutational spectrum for th e DYSF gene, with a high proportion of missense changes, or frameshifting insertions and/or deletions (for example, (Aoki, et al., 2001; Cagliani, et al., 2003; De Luna, et al., 2007; Guglieri, et al., 2008; Klinge, et al., 2010; Krahn, et al., 2009a; Mahjneh, et al., 1996; Nguyen, et al., 2005; Tagawa, et al., 2003; Takahashi, et al., 2003) ). Accordingly, most of th e UMD -DYSF ent ries corres pond to " private" or ra re DYSF disease-causing mutations. In th e 401 reported index patients, 266 disease-causing variants were identified along the DYSF coding sequence. Within the index cases population, 379 het erozygous variants and 178 h omozygous variants were identified and constitute a set of 735 alleles.
Founder mutations and recurrent mutations
Among DYSF d isease-causing mutations, se ven d ifferent fo under mutations have b een su ggested o r demonstrated i n pat ients of v arious geographic/ethnic origins ( Argov, et al ., 2000; C agliani, et al ., 2003; Leshinsky-Silver, et a l., 2007 ; S antos, et al ., 2010; V ernengo, et al ., 2011; V ilchez, et a l., 2005; Wei ler, et al ., 1999) (Table 2 ). In addition, interrogation of the database shows that 51 mutations have been recurrently identified in at least th ree non-related in dex p atients (see u pdated list o n th e UMD -DYSF website). T hese recu rrent mutations are di stributed al ong t he codi ng s equence a nd canonic s plice s ites without any apparen t mutational « hotspot » (Figure 1) . 
Type of mutational events
Among the 266 different reported mutational events, the following type of mutations were identified: 175 single base su bstitutions (65.8% ), 54 del etions (20.3% ), 26 du plications (9.8% ), 6 i nsertions (2.3% ) an d 5 insertion/deletions (1 .9%). Am ong t he to tal d eletion an d in sertion e vents, 5 1.8% o f deletions a nd 6 8.7% o f insertions occurred within a repeated sequence. A total of 220 (82.7%) distinct mutations affect exonic sequences and th e re maining 4 6 (1 7.3%) m utations i nvolve c hange o f in tronic n ucleotides. Altogether, a mong all d iseasecausing mutations i n U MD-DYSF, e xonic mutations s egregate into missense mutations (33.1% ), n onsense mutations (18.0% ), f rameshifting mutations (27.8% ) a nd i n-frame ex onic i nsertions or del etions (3.8% ) ( Table 3A ). The partition of the different mutation types found within the UMD-DYSF allele set is summarized in Table 3B . M oreover, U MD-DYSF r eports si x l arge r earrangements fo und i n e ight i ndex p atients i nvolving deletion or du plication of on e or s everal e xons (T able 4). B ecause s uch larg e mutational e vents are n ot systematically search ed for in g enetic tes ting, t his figure is ex pected to be an u nderestimate of t he real larg e rearrangements frequency (Krahn, et al., 2009b) . Large deletions can be displayed using the "Deletion Map" function on the UMD-DYSF website. Mutations are described using the o fficial n omenclature o f t he Hu man Genome V ariation S ociety, an d rel ating t o t he hu man DYSF c DNA s equence of reference (isoform 8, GenBank #NM_003494.2).
Exonic variants
The 220 exonic mutations are distributed along the entire coding sequence, affecting regions of the protein both within or outside of predicted functional domains, and without any defined mutational hotspot (Figure 1) . A total of 122 exonic mutations are predicted to disrupt the open reading frame and/or to lead to a premature stop codon. These mutations ca n b e class ified in to i nsertions o r d eletions ev ents (7 4 f rameshifting mutations) an d n onsense mutations (48 mutations) (T able 3A) an d are found e venly di stributed al ong the codi ng s equence (Fi gure 1). Overall, the events that presumably lead to t he translation of a tr uncated and unstable dysferlin protein represent 50.6% of the proband allele population (Table 3B ). We examined the distribution of missense and in-frame exonic insertion or del etion mutations a nd co mpared t heir proport ion ei ther within or out side ann otated do mains (Figure 1) . We s how t hat mutations recorded i n U MD-DYSF aff ect 3.3% of al l am ino aci ds res iding ou tside annotated do mains a nd 5.0% of al l a mino aci ds res iding within do mains. In part icular, we conf irm t he susceptibility of the repeated DysF domain to mutations (Patel, et al., 2 008) as th e UMD-DYSF mutations affect 7.9% of t he a mino aci ds within t his do main. T he " Structure" fu nction s ummarizes t he dis tribution of s mall rearrangements in structural domains and in possible calcium binding residues of the dysferlin protein. Within the group of proband alleles, 453 (81.3%) correspond to DYSF variants mutated within regions encoding a predi cted structural or f unctional do main. O verall, C2 do mains are t he most f requently a ffected (266 m utational e ntries), followed b y D ysF a nd f erlin dom ains (126 an d 60 m utational en tries, res pectively) whereas on e si ngle i ndex patient was identified with a deleterious mutation (12 bp insertion/deletion) in the region coding for the carboxyterminal t ransmembrane do main (G uglieri, et al ., 2008) . I nterestingly, mutations i n pr edicted cal cium bi nding residues of C2 domains were reported for only three patients, within C2B, C2C and C2F domains (De Luna, et al., 2007; Nguyen, et al., 2005; Walter, et al., 2003) .
Splice variants
Among the 266 different mutational events reported in UMD-DYSF, 46 splice variants consist of both intronic or exonic mutations associated with a predi cted or ex perimentally described abnormal splicing of t he DYSF gene (Table 5 ). Intronic v ariants i nclude 31 mutations di rectly a ffecting 5 ' splice don or-sites, 14 m utations aff ecting 3' splice acceptor-sites and one deleterious mutation within a branchpoint signal. In addition, two exonic mutations have been shown to produ ce aberran tly spliced trans cripts b y ei ther abolis hing t he ca nonical don or s plice s ite (c.5429G>A) (Santos, et al., 2010 ) or by creating a n ovel ectopic acceptor splice site (c.1555G>A) (De L una, et al., 200 7) . A ltogether, s plice v ariants con stitute 14.8% of t he al lele popu lation i n U MD-DYSF i ndex pat ients (Table 3B ). U sing dedi cated f unctions i ncluded i n U MD and H SF, a pat hogenic e ffect on t he s plice don or or acceptor sites, or in the branchpoint (c.3443-33A>G), was correctly predicted in all cases, exception made for one mutation, c.5525+3A >G. T his mutation was sh own to pro mote ex on 49 s kipping (D e Luna, et a l., 2007) . H SF analysis predicts a n e ffect on t he splice donor site, but bel ow t he threshold of pat hogenicity. However, possible effects on exonic splicing enhancer and silencer sites are also predicted, and may cause the experimentally proven exon 49 skipping in this case.
Mutation status
Altogether, 280 patients carry at least one homozygous mutation. Among them, two patients carry two or three homozygous mutations (F 1-47-1-2 an d F 1-18-1-2) an d t hree pat ients carr y on e homozygous mutation a nd on e heterozygous mutation (U K2-29-1-0, U K2-47-1-0 a nd U K2-49-1-0). A t otal of 176 pat ients carr y a t l east t wo compound heterozygous mutations, including two patients carrying three heterozygous mutations (F1-65-1-2 and UK2-35-1-0). The identification of more than two distinct possibly disease-causing mutations in a patient may be related t o t he ex istence o f hypomorphic sequence v ariants, or co mplex a lleles. F or 102 pat ients, on ly on e heterozygous disease-causing m utation w as iden tified. Am ong these are two s ymptomatic dysferlin m utation carriers described by Illa and colleagues (Illa, et al., 2007) . Overall, both disease-causing alleles were identified in 323 i ndex pat ients (80.5% ), whereas on ly on e di sease-causing al lele was i dentified i n t he ot her 78 i ndex cas es (19.5%), th us underlining i ncomplete se nsitivity o f th e cu rrently u sed mutation d etection tec hniques. Ho wever, these figures do n ot reflect the overall detection rate of dysferlin mutation screening procedures since in patients with a cli nical d iagnosis o f dysferlinopathy, it is e stimated th at f or ap proximately 1 0% o f th em, mutational analyses did not confirm them as carriers of any disease-causing mutation in the dysferlin gene and these patients are th us n ot reco rded in UM D-DYSF (th e in clusion criter ia b eing th e id entification o f at least o ne d eleterious mutation). Liu et al. 1998 Mutations affect canonical intronic splice signals (5' and 3'splice sites, branchpoints) or exonic nucleotides. Effect on R NA splicing was either predicted (r.spl?) or experimentally described. Disruption of canonical splice signals or creation of novel splice s ignals c an pr omote ex on s kipping ( ES), i ntron r etention (IR), or ot her s equence ins ertion/deletion in t he m RNA.
Mutations are predicted to either maintain the reading frame (IF) or introduce a frameshift (FS) leading to the translation of a truncated product and possibly to nonsense-mediated mRNA decay. * Predominant transcript. Mutations are described using the of ficial no menclature of the Human Genome Va riation Soc iety, a nd r elating to the hum an DYSF c DNA s equence of reference (isoform 8, GenBank #NM_003494.2).
Comparison of mutational profiles of the LGMD2B and Miyoshi myopathy phenotypes
Dysferlinopathies are ch aracterized by th e t wo main cli nical ph enotypes, LGMD2B an d Miy oshi myopathy, and additional clinical variants, thus presenting a b road range of symptoms a nd onset. In all cases th e genotypephenotype rel ationship has al ways re mained di fficult t o d efine. In U MD-DYSF, 88% of pat ients pres ent with either a L GMD2B or Mi yoshi myopathy phenotype, as described in the original publications. We h ave compared the distribution of the mutations along the DYSF gene (Figure 1 ) and the type of mutations between the two main clinical groups (Table 3C and D, with patients with one homozygous mutation) and no significant difference was observed bet ween t hem (Chi 2 test, p>0.01). Therefore, available mutational data do not point out a ny genotypephenotype co rrelation for d ysferlin mutations with re gard to th e t wo main cl inical p resentations, LGMD2B o r Miyoshi myopathy. It can be speculated that the observed clinical heterogeneity in dysferlinopathies may rather be related to the implication of genetic or environmental modifiers.
DATABASE UPDATE
The UMD-DYSF v 1.0 databas e an d s ubsequent u pdated v ersions are av ailable at www .umd.be/DYSF/. Curation o f the UMD-DYSF d atabase b y a d edicated cu rator will al low co ntinuous updating. Cl inicians an d researchers are en couraged to s ubmit unpublished variants by contacting the curator of the database. Notification of omissions and errors in the current version, as well as specific phenotypic data, would be gratefully received by the curator. The software package is available on a collaborative basis and will be expanded as the database grows, with the implementation of new specific functions according to the requirements of its users. In referring to UMD-DYSF, we kindly ask all users of the database to cite this article.
